Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 4, 2016, Pages 428-436

  Zash, Rebecca ^a,b,c   Souda, Sajini ^d   Chen, Jennifer Y ^e   Binda, Kelebogile ^b   Dryden Peterson, Scott ^b,c,f   Lockman, Shahin ^b,c,f   Mmalane, Mompati ^b   Makhema, Joseph ^b   Essex, Max ^b,c   Shapiro, Roger ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF BOTSWANA   (Botswana)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; HIV; PMTCT; Preterm delivery; Small for gestational age; Stillbirth

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ; EMTRICITABINE; TENOFOVIR;

ADULT; ADVERSE OUTCOME; BOTSWANA; CD4 LYMPHOCYTE COUNT; CONCEPTION; CONFERENCE PAPER; DELIVERY; DISEASE TRANSMISSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONOTHERAPY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; SMALL FOR DATE INFANT; STILLBIRTH; COMBINATION DRUG THERAPY; HIV INFECTIONS; NEWBORN; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BOTSWANA; DRUG THERAPY, COMBINATION; EMTRICITABINE; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; TENOFOVIR;

EID: 84960244192     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000847     Document Type: Conference Paper

References (42)

1. World Health Organization. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva, Switzerland: 2013. Available at: http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport. Accessed October 18, 2015.
2. Ciaranello AL, Perez F, Keatinge J, et al. What will it take to eliminate pediatric HIV? Reaching who target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012;9:e1001156.
3. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization Programme; 2013. Available at: http://apps. who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed October 19, 2015.
4. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
5. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
6. Elzi L, Erb S, Furrer H, et al. Choice of initial combination antiretroviral therapy in individuals with HIV infection: determinants and outcomes. Arch Intern Med. 2012;172:1313-1321.
7. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68:567-578.
8. Bangsberg DR, Mills EJ. Long-term adherence to antiretroviral therapy in resource-limited settings: a bitter pill to swallow. Antivir Ther. 2013; 18:25-28.
9. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtrici-tabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011-1020.
10. Semvua HH, Mtabho CM, Fillekes Q, et al. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Antivir Ther. 2013;18:105-113.
11. dos Santos AP, Pacheco AG, Staviack A, et al. Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tuberc Lung Dis. 2013;17:192-197.
12. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14:1039-1043.
13. Coutsoudis A, Goga A, Desmond C, et al. Is option B+ the best choice? Lancet. 2013;381:269-271.
14. WHO HIV/AIDS Programme. Use of Efavirenz During Pregnancy: A Public Health Perspective. 2012. Available at: http://www.who.int/hiv/pub/treatment2/efavirenz/en/index.html. Accessed October 19, 2015.
15. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695-1705.
16. Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607-615.
17. Food and Drug Administration. Supplement: safety and toxicity of individual antiretroviral agents in pregnancy: update may 24. Available at: http://aidsinfo.nih.gov/contentfiles/perinatalglsafetytox-sup.pdf. Accessed October 19, 2015.
18. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-1026.
19. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active anti-retroviral therapy. AIDS. 2006;20:59-66.
20. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS. 2008;22:1815-1820.
21. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis. 2007; 196:558-561.
22. Shapiro RL, Souda S, Parekh N, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLoS One. 2012;7:e31580.
23. Botswana National HIV & AIDS Treatment Guidelines, 2012 Version. 1. April 2012 Edition. Available at: http://www.moh.gov.bw/Publications/HIVAIDS%20TREATMENT%20GUIDELINES.pdf. Accessed October 19, 2015.
24. Statistics Botswana. Health Statistics Report 2009. Available at: http://www. cso.gov.bw/index.php/sector-statistics/health. Accessed October 19, 2015.
25. Matthews L, Ribaudo H, Parekh N, et al. Birthweight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for US-born black infants. BMC Pediatr. 2011;11:115.
26. World Health Organization. Weight Percentiles Calculator. Available at: www.who.int/reproductivehealth/topics/best-practices/weight-percentiles- calculator.xls. Accessed October 19, 2015.
27. Ezechi OC, Gab-Okafor CV, Oladele DA, et al. Pregnancy, obstetric and neonatal outcomes in HIV positive Nigerian women. Afr J Reprod Health. 2013;17:160-168.
28. Turner AN, Tabbah S, Mwapasa V, et al. Severity of maternal HIV-1 disease is associated with adverse birth outcomes in Malawian women: a cohort study. J Acquir Immune Defic Syndr. 2013;64:392-399.
29. Cailhol J, Jourdain G, Coeur SL, et al; Perinatal HIV Prevention Trial Group. Association of low CD4 cell count and intrauterine growth retardation in Thailand. J Acquir Immune Defic Syndr. 2009;50:409-413.
30. Fowler MG, Qin M, Shapiro D, et al. PROMISE: efficacy and safety of 2 strategies to prevent perinatal HIV transmission. Paper Presented at: CROI; February 2015; Seattle, WA.
31. Sibiude J, Warszowski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost. Clin Infect Dis. 2012;54:1348-1360.
32. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother to child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11:171-180.
33. Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS. 2009;23:1235-1243.
34. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
35. Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigaton of systemic and intracellular interactions between TDF and abacavir, lamivudine or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937-1943.
36. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritona-vir. J Acquir Immune Defic Syndr. 2006;34:278-283.
37. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States-September 14, 2011. Available at: https://aidsinfo.nih.gov/contentfiles/PerinatalGL002799.pdf. Accessed October 19, 2016.
38. UNICEF, WHO, World Bank, UN DESA/Population Division. Levels and Trends in Child Mortality 2014. UNICEF; 2014. Available at: http://www.unicef.org/media/files/Levels-and-Trends-in-Child-Mortality- 2014.pdf. Accessed October 19, 2015.
39. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? Lancet. 2005;365:891-900.
40. Powis K, Shapiro RL. Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle? J Infect Dis. 2015;211:4-7.
41. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211:10-18.
42. Fiore S, Ferrazzi E, Newell ML, et al. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis. 2007;195:914-916.